CR
CRBP.US Corbus Pharmaceuticals Holding
- Market cap
- USD 69.9M
- P/E
- -
- P/B
- 0.83x
- ROE
- -150.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is CRBP.US undervalued?
Graham numberThe Graham number of Corbus Pharmaceuticals Holding cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Corbus Pharmaceuticals Holding fundamental analysis
No fundamental analysis for Corbus Pharmaceuticals Holding yet.
Corbus Pharmaceuticals Holding stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Corbus Pharmaceuticals Holding
Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in No…
Full company profileCorbus Pharmaceuticals Holding financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Corbus Pharmaceuticals Holding annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.91M | 2.44M | 4.82M | 36.1M | 3.94M | 882K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -13.5M | -23.6M | -43.8M | -53.5M | 3.94M | -758K | -1.49M | -31.2M | -600K | -233K | - |
| Operating Income | -20.0M | -32.6M | -56.7M | -77.1M | -123M | -56.0M | -34.8M | -45.1M | -48.7M | -85.3M | -132M |
| EBITDA | -19.9M | -32.3M | -56.3M | -75.9M | -121M | -42.2M | -38.7M | -40.1M | -37.7M | -78.3M | -127M |
| Net Income | -20.0M | -32.4M | -55.7M | -71.5M | -111M | -45.6M | -55.8M | -44.6M | -40.2M | -78.5M | -128M |
| EPS | -15 | -19 | -29 | -34 | -43 | -11 | -13 | -10 | -3.68 | -5.90 | -6.13 |
| Balance Sheet | |||||||||||
| Total Assets | 17.9M | 67.0M | 47.0M | 49.1M | 102M | 108M | 66.3M | 28.3M | 156M | 168M | 123M |
| Total Liabilities | 8.97M | 9.19M | 19.5M | 43.0M | 57.0M | 38.6M | 33.3M | 35.2M | 13.5M | 20.7M | 38.1M |
| Shareholders' Equity | 8.92M | 57.8M | 27.5M | 6.16M | 45.3M | 69.1M | 33.0M | -6.91M | 142M | 148M | 84.8M |
| Cash & Short-term Investments | 15.0M | 62.5M | 41.7M | 31.7M | 85.4M | 97.6M | 59.2M | 20.9M | 149M | 164M | 115M |
| Total Debt | 276K | 333K | 394K | 9.45M | 26.8M | 26.6M | 25.1M | 20.9M | 3.24M | 1.63M | 3.91M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -13.6M | -27.8M | -30.1M | -45.7M | -99.7M | -48.2M | -37.5M | -36.1B | -41.8M | -64.5M | -102M |
| Capital Expenditure | 353K | 707K | 2.30M | 2.74M | 484K | 54.2K | 13.4K | 3.00 | 0.00 | 7.00K | 36.0K |
| Free Cash Flow | -13.9M | -28.5M | -32.4M | -48.5M | -100M | -48.2M | -37.6M | -36.1B | -41.8M | -64.5M | -102M |
| Ratios | |||||||||||
| ROE | -224.2% | -56.1% | -202.3% | -1,160.4% | -245.8% | -65.9% | -169.2% | - | -28.2% | -53.2% | -150.6% |
| ROA | -111.8% | -48.4% | -118.5% | -145.4% | -108.8% | -42.3% | -84.2% | -157.8% | -25.8% | -46.7% | -103.9% |
| Net Profit Margin | -1,046.3% | -1,328.6% | -1,154.5% | -197.7% | -2,826.1% | -5,166.4% | - | - | - | - | - |
| Debt to Equity | 0.03x | 0.01x | 0.01x | 1.53x | 0.59x | 0.38x | 0.76x | - | 0.02x | 0.01x | 0.05x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Corbus Pharmaceuticals Holding dividends
Corbus Pharmaceuticals Holding has not paid dividends in the last 9 fiscal years.
Last stock split: 1:30 on Feb 14, 2023.
Who owns Corbus Pharmaceuticals Holding
- Insiders 1.75%
- Institutions 69.70%
- Public & others 28.55%
- Shares outstanding 20.6M
- Free float 15.4M
Top funds holding CRBP.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Biotech Growth Ord | 539K | 2.78% | 0.00% | Jul 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 534K | 2.76% | 0.00% | Sep 2026 |
| abrdn Healthcare Investors | 434K | 2.24% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 420K | 2.17% | 0.00% | Oct 2026 |
| International Biotechnology Ord | 227K | 1.18% | 0.00% | Jul 2026 |
| Fidelity Small Cap Index | 187K | 0.97% | +4.29% | Aug 2026 |
| Global X Marijuana Life Sciences ETF | 173K | 0.90% | +20.87% | Sep 2026 |
| iShares Russell 2000 Value ETF | 157K | 0.81% | 0.00% | Oct 2026 |
| Vanguard Russell 2000 ETF | 99.5K | 0.51% | +5.09% | Sep 2026 |
| Fidelity Enhanced Small Cap Core ETF | 94.1K | 0.49% | +0.27% | Oct 2026 |
| A4Investments SICAV SIF ACCI IlanaA2EURH | 90.0K | 0.47% | 0.00% | Oct 2026 |
| Fidelity Extended Market Index | 80.1K | 0.41% | +63.04% | Sep 2026 |
| Dimensional US Small Cap ETF | 58.4K | 0.30% | 0.00% | Oct 2026 |
| Bridge Builder Small Cap Fund | 56.2K | 0.29% | 0.00% | Oct 2026 |
| iShares Micro-Cap ETF | 51.7K | 0.27% | 0.00% | Oct 2026 |
| Schwab Small Cap Index | 44.8K | 0.23% | +12.81% | Sep 2026 |
| CREF Total Global Stock Account R3 | 40.6K | 0.21% | 0.00% | Aug 2026 |
| DFA US Micro Cap I | 39.7K | 0.21% | 0.00% | Sep 2026 |
| Fidelity VIP Disciplined Small Cap Init | 34.3K | 0.18% | 0.00% | Aug 2026 |
| iShares Russell 2000 Small-Cap Idx Instl | 30.8K | 0.16% | 0.00% | Sep 2026 |
Top institutions holding CRBP.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Cormorant Asset Management, LLC | 2.34M | 12.12% | 0.00% | Jun 2026 |
| Orbimed Advisors LLC | 1.74M | 8.98% | 0.00% | Jun 2026 |
| BlackRock Inc | 1.33M | 6.88% | +390.04% | Jun 2026 |
| Aberdeen Group PLC | 1.32M | 6.83% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 761K | 3.93% | +3.66% | Jun 2026 |
| Jones Hill Capital LP | 654K | 3.38% | 0.00% | Jun 2026 |
| Prosight Management, LP | 650K | 3.36% | -6.76% | Jun 2026 |
| Stonepine Capital Management Llc | 425K | 2.20% | +10.83% | Jun 2026 |
| Geode Capital Management, LLC | 423K | 2.19% | +126.37% | Jun 2026 |
| ADAR1 Capital Management LLC | 422K | 2.18% | +27.13% | Jun 2026 |
| Diadema Partners LP | 301K | 1.56% | -31.52% | Jun 2026 |
| Susquehanna International Group, LLP | 293K | 1.52% | -12.06% | Jun 2026 |
| State Street Corp | 255K | 1.32% | +269.78% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 210K | 1.09% | +10.57% | Sep 2026 |
| Exome Asset Management LLC | 185K | 0.96% | -21.02% | Jun 2026 |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 152K | 0.78% | -5.50% | Jun 2026 |
| Jane Street Group LLC | 139K | 0.72% | +90.09% | Jun 2026 |
| Northern Trust Corp | 125K | 0.65% | +200.95% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 112K | 0.58% | +16.79% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 111K | 0.58% | +356.81% | Jun 2026 |
Corbus Pharmaceuticals Holding company profile
- Company name
- Corbus Pharmaceuticals Holding
- Ticker
- CRBP.US
- Exchange
- USA Stocks
- Listed since
- Nov 11, 2014
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 36
- Fiscal year end
- December
- Address
- 500 River Ridge Drive, Norwood, MA, United States, 02062
- Phone
- 617 963 0100
- Website
- corbuspharma.com
About Corbus Pharmaceuticals Holding
Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts.
Corbus Pharmaceuticals Holding management
7- Dr. Yuval Cohen Ph.D.CEO & Director · born 1975
- Mr. Sean F. Moran CPA, M.B.A.Chief Financial Officer · born 1958
- Dr. Ian Hodgson B.Sc., Ph.D.Chief Operating Officer · born 1973
- Mr. G. Scott Goeken J.D., M.S.General Counsel & Corporate Secretary
- Ms. Christina Bertsch M.A.Vice President of Human Resources
- Mr. Nishant C. SaxenaChief Business Officer
- Dr. Leonardo Viana Nicacio M.D.Chief Medical Officer · born 1978